The Role and Mechanism of GPER-Hippo-CBS/H2S Pathway in Preeclampsia

NCT06205771 | Enrolling By Invitation

• 1 other identifier: YXLL-KY-2023（031）
• Study Type: interventional
• Target: 54
• Locations: 1 country
• Sites: 1

Brief Summary

The goal of this clinical trial is to learn about in health conditions. The main questions it aims to answer are:

• The pathological significance of GPER in uterine artery dilation in preeclampsia
• The Mechanism of GPER Hippo Pathway Regulating CBS/H2S in Human Uterine Artery Smooth Muscle Cells (hUASMC) This project intends to use GPER interfering RNA, YAP1 interfering RNA, in vivo perfusion experiments of human uterine artery tissue, and single cell patch clamp technology to study hypotheses under physiological/pathological pregnancy conditions at the tissue, cellular, and molecular levels, revealing a novel signal transduction pathway of estrogen stimulating vasodilation, providing new ideas for studying the mechanism of uterine artery blood flow regulation. This research result will provide new targets for intervention and treatment of diseases such as fetal intrauterine growth retardation and preeclampsia.

Conditions

Preeclampsia

Keywords

preeclampsia

Outcome Measures

Primary Outcomes (1)

• H2S content in uterine arterial smooth muscle circulation

  H2S content in circulation

  8:00 am

Study Arms (2)

NP

NO INTERVENTION

normal pregnancy and preeclampsia pregnancy

PE

EXPERIMENTAL

preeclampsia

Other: H2S content

Interventions

H2S content OTHER

H2S content

PE

Eligibility Criteria

• Age: Up to 40 Years
• Sex: female
• Healthy Volunteers: Yes
• Age Groups: Child (0-17), Adult (18-64)

You may qualify if:

• Full term pregnancy with clinical diagnosis of preeclampsia and normal pregnancy pregnant woman
• Pregnant women undergoing lower segment cesarean section for delivery

You may not qualify if:

• Combined with chronic hypertension, kidney disease, intrahepatic cholestasis, etc Other basic diseases;
• Multiple pregnancy
• Pregnant women undergoing vaginal delivery
• Normal pregnant women who are\<37 weeks or\>40 weeks pregnant

Sponsors & Collaborators

• Hao Feng: lead

Study Sites (1)

The First Affiliated Hospital of Shandong First Medical University &Shandong Provincial Qianfoshan Hospital

Jinan, Please Select, 250000, China

Location

MeSH Terms

Conditions

Pre-Eclampsia

Condition Hierarchy (Ancestors)

Hypertension, Pregnancy-Induced; Pregnancy Complications; Female Urogenital Diseases and Pregnancy Complications; Urogenital Diseases

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: BASIC SCIENCE
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR INVESTIGATOR
• PI Title: professor

Study Record Dates

• First Submitted: January 4, 2024
• First Posted: January 16, 2024
• Study Start: April 10, 2024
• Primary Completion (Estimated): October 1, 2029
• Study Completion (Estimated): December 1, 2029
• Last Updated: April 10, 2024

Record last verified: 2024-01

Locations

CN (1)